HRTX Earnings

HRTX reported its FY2025Q4 earnings on 2026-03-09, showcasing a revenue of against an estimate of 39.55M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.03 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following HRTX's FY2025Q4 earnings announcement on 2026-03-09, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, HRTX's stock price tends to shift by an average of 9.93% in the 10 days leading up to earnings and 17.21% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate HRTX's annual revenue to reach 39.03M, while the EPS is projected at -0.01. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between HRTX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, HRTX's stock price typically moves by 9.93% in the 10 days before its earnings and 17.21% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -0.01 and revenue of 39.03M.

The earnings call highlights strong growth in Acute Care products, particularly ZYNRELEF and APONVIE, with optimistic future guidance and strategic initiatives. Despite some competitive and regulatory challenges, the company exceeded its financial guidance, showing resilience. The Q&A session provided additional positive insights, especially regarding the beneficial impact of the NOPAIN Act and new guidelines for APONVIE. However, some uncertainties remain, such as the litigation outcome and the exact impact timelines. Overall, the strong financial performance and growth potential suggest a positive stock price movement.